Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Mar 28;3(2):107-14.
doi: 10.1111/j.2040-1124.2011.00191.x.

Controlling the receptor for advanced glycation end-products to conquer diabetic vascular complications

Yasuhiko Yamamoto  1 , Hiroshi Yamamoto  1
Affiliations
Review

Controlling the receptor for advanced glycation end-products to conquer diabetic vascular complications

Yasuhiko Yamamoto et al. J Diabetes Investig. .

Abstract

Diabetic vascular complications, such as cardiovascular disease, stroke and microangiopathy, lead to high rates of morbidity and mortality in patients with long-term diabetes. Extensive intracellular and extracellular formation of advanced glycation end-products (AGE) is considered a causative factor in vascular injuries in diabetes. Receptor-dependent mechanisms are involved in AGE-induced cellular dysfunction and tissue damage. The receptor for AGE (RAGE), originally an AGE-binding receptor, is now recognized as a member of pattern-recognition receptors and a pro-inflammatory molecular device that mediates danger signals to the body. Previous animal studies have shown RAGE dependent of diabetic vascular injuries. Prophylactic and therapeutic strategies focusing on RAGE and its ligand axis will be of great importance in conquering diabetic vascular complications. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2011.00191.x, 2012).

Keywords: Advanced glycation end‐products; Diabetic vascular complications; Receptor for advanced glycation end‐products.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Possible pathways of advanced glycation end‐products (AGE) formation. This is adapted from a review paper by Monnier et al.95. The classical pathway leading to the formation of AGE involves Schiff base and Amadori products. The Amadori products can be transformed into reactive dicarbonyl products, such as glucosones, and can be fragmented by oxidation (glycoxidation) to generate pentosidine and Nε‐carboxymethyl‐lysine (CML). Reactive dicarbonyls can also be generated from ketones, lipids, glycolysis and inflammatory pathways. Representative AGE are presented here. CEL, Nε‐carboxyethyl‐lysine; 3‐DG‐imidazolone, 3‐deoxyglucosone‐imidazolone; GA‐pyridine, glycolaldehyde‐pyridine; GLAP, glyceraldehyde‐related pyridinium; GOLD, glyoxal‐derived lysine dimer; MG‐hydroimidazolone, methylglyoxal‐derived hydroimidazolone; MOLD, methylglyoxal‐derived lysine dimer.
Figure 2
Figure 2
Receptor for advanced glycation end‐products (RAGE) and its multiple ligands in the development of diabetic vascular complications. Soluble RAGE (sRAGE) and endogenous soluble RAGE (esRAGE) might work as decoy receptors against ligand‐receptor interactions. This is adapted from our review paper96. AGE, advanced glycation end‐products; AOPP, advanced oxidation protein products; HMGB1, high‐mobility group box protein 1; NF‐κB, nuclear factor‐κB; PRR, pattern‐recognition receptors; TLR, toll‐like receptors.
Figure 3
Figure 3
Phenotypes of diabetic nephropathy in receptor for advanced glycation end‐products (RAGE) gene‐manipulated mice. KO, knockout mice; Tg, transgenic mice.
Figure 4
Figure 4
Splice variants of human and mouse receptor for advanced glycation end‐products (RAGE) genes. This is adapted from our original paper97. esRAGE, endogenous secretory RAGE; ORF, open reading frame.
See this image and copyright information in PMC

References

    1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country‐years and 2.7 million participants. Lancet 2011; 378: 31–40 - PubMed
    1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010; 87: 4–14 - PubMed
    1. Pacher P, Szabó C. Role of poly(ADP‐ribose) polymerase‐1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid Redox Signal 2005; 7: 1568–1580 - PMC - PubMed
    1. Maillard LC. Action des acides amine’s surles sucres: formation des melanoides par voie methodique. C R Acad Sci 1912; 154: 66–68
    1. Yamamoto H, Watanabe T, Yamamoto Y, et al. RAGE in diabetic nephropathy. Curr Mol Med 2007; 7: 752–757 - PubMed